Sunshine Biopharma, Inc. is a pharmaceutical company. The Company focuses on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound is Adva-27a, which is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. The Company's Adva-27a is a Topoisomerase II inhibitor. Adva-27a is used against various multidrug resistant cancer cells: Breast Cancer Cells (MCF-7/MDR), Small Cell Lung Cancer Cells (H69AR), Uterine Cancer (MES-SA/Dx5) and Pancreatic Cancer (Panc-1). Adva-27a has a clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats. The Company is focuses on conducting Phase I clinical trials for Adva-27a.